Search

Showing total 5 results
5 results

1. ARVO 2024: A cascade of content in Seattle.

Author

Hutton, David

Subjects
*LECTURE method in teaching, *DIFFUSION of innovations, *MEDICAL technology, *ARTIFICIAL intelligence, *CONFERENCES & conventions, *OPHTHALMOLOGY, *PROFESSIONAL employee training, *AWARDS
Abstract

The article provides information on the 2024 annual meeting concluded by the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington with content and presentations that showed the level of innovation on the field of ophthalmology. Topics include number of posters and paper sessions featured in the event, mission of ARVO, and the meeting's focus on the impact of innovation, technology, and information on vision research.

Published
2024

2. More than 5,500 scientific paper, poster presentations will be delivered during 5-day event.

Author

Charters, Lynda

Subjects
*OPHTHALMOLOGY, *EYE diseases, *CONFERENCES & conventions, *RETINAL degeneration, *T cells
Abstract

Focuses on the theme of the annual meeting of the Association for Research in Vision and Ophthalmology in Fort Lauderdale, Florida, on May 1-5, 2005. Expected number of scientific paper and poster presentations; Presentation on ocular oncology collaborative research; Discussions on age-related macular degeneration and regulatory T cells in ocular pathology.

Published
2005

3. ARVO: Sight set on world-class science.

Subjects
*THERAPEUTIC use of antioxidants, *RETINAL degeneration, *HETEROCYCLIC compounds, *OPHTHALMOLOGY, *CONFERENCES & conventions, *DRY eye syndromes, *ENZYME inhibitors, *GLAUCOMA, *MICROSCOPY, *OPHTHALMIC drugs, *PROTEINS, *RETINAL diseases, *TEARS (Body fluid), *PREVENTION, *SOCIETIES
Abstract

Information about several papers discussed at the Association for Research in Vision and Ophthalmology (ARVO) meeting in 2013 is presented. Age-Related Eye Disease Study 2 (AREDS2) results showed that participants treated with the antioxidants lutein and zeaxanthin without beta-carotene had their risk of age-related macular degeneration (AMD) reduced at about 18%. Automated standardization in evaluating corneal superficial punctuate keratitis (SPK) is shown not to be invariably applicable.

Published
2013

4. Aging eye is focus of ARVO meeting in 2007.

Author

Abelson, Mark B. and Lilyestrom, Lauren

Subjects
*EYE diseases, *RETINAL degeneration, *CONFERENCES & conventions, *OPHTHALMOLOGY
Abstract

The article presents information on several research papers related to aging eye discussed at the Association for Research in Vision and Ophthalmology's (AVRO) annual meeting held in 2007. A study had found that mean retinal thickness decreased significantly after 3 months of treatment in patients with wet age-related macular degeneration. Information is given on research related to several diseases of eye including blepharitis, dry eye, and glaucoma.

Published
2007

5. Intravitreal bevacizumab promising for ischemic CRVO.

Author

Kozielec, Gregory F.

Subjects
*CONFERENCES & conventions, *OPHTHALMOLOGY, *EDEMA, *METABOLIC disorder treatment
Abstract

Information about several papers discussed at the 2007 annual meeting of the American Academy of Ophthalmology in Las Vegas, Nevada is presented. Gregory F. Kozielec asserted that a study on intravitreal bevacizumab by Avastin and Genentec has shown positive results for the treatment for macular edema associated with ischemic central retinal vein occlusion. He asserted that the achieved results are encouraging but preliminary.

Published
2007